News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
38,155 Results
Type
Article (2768)
Press Release (35387)
Section
Business (11462)
Career Advice (15)
Deals (2670)
Drug Delivery (1)
Drug Development (4315)
Employer Resources (2)
FDA (959)
Job Trends (711)
News (19673)
Policy (1829)
Tag
Academia (109)
Allergies (1)
Alliances (2984)
Alzheimer's disease (34)
Antibody-drug conjugate (ADC) (3)
Approvals (970)
Artificial intelligence (4)
Autoimmune disease (1)
Bankruptcy (17)
Best Places to Work (419)
Brain cancer (2)
Breast cancer (4)
Cancer (65)
Cardiovascular disease (1)
Career advice (14)
CAR-T (4)
Cell therapy (19)
Clinical research (3524)
Collaboration (35)
Compensation (17)
COVID-19 (353)
C-suite (26)
Cystic fibrosis (7)
Data (82)
Depression (3)
Diabetes (9)
Diagnostics (262)
Digital health (2)
Diversity, equity & inclusion (1)
Drug discovery (1)
Drug pricing (1)
Duchenne muscular dystrophy (2)
Earnings (4037)
Employer resources (2)
Events (4010)
Executive appointments (51)
FDA (1007)
Funding (30)
Gene therapy (9)
GLP-1 (24)
Government (173)
Guidances (2)
Healthcare (639)
Indications (1)
Infectious disease (361)
Inflammatory bowel disease (3)
Influenza (1)
Intellectual property (1)
IPO (869)
IRA (1)
Job creations (307)
Job search strategy (14)
Layoffs (13)
Legal (554)
Liver cancer (4)
Lung cancer (8)
Lymphoma (1)
Management (1)
Manufacturing (9)
MASH (1)
Medical device (466)
Medtech (466)
Mergers & acquisitions (1816)
Metabolic disorders (18)
Neuropsychiatric disorders (2)
Neuroscience (50)
NextGen: Class of 2025 (130)
Non-profit (59)
Northern California (48)
Now hiring (1)
Obesity (7)
Opinion (7)
Ovarian cancer (6)
Pain (1)
Parkinson's disease (3)
Partnered (1)
Patents (4)
Patient recruitment (3)
Peanut (1)
People (4167)
Phase I (900)
Phase II (1398)
Phase III (1442)
Pipeline (44)
Policy (1)
Postmarket research (277)
Preclinical (299)
Press Release (1)
Prostate cancer (4)
Radiopharmaceuticals (21)
Rare diseases (15)
Real estate (248)
Regulatory (1185)
Reports (6)
Research institute (103)
RSV (4)
Schizophrenia (3)
Series A (7)
Series B (4)
Sickle cell disease (1)
Southern California (44)
Spinal muscular atrophy (5)
Startups (202)
United States (588)
Vaccines (57)
Webinars (1)
Weight loss (2)
Date
Today (6)
Last 7 days (18)
Last 30 days (104)
Last 365 days (1416)
2025 (308)
2024 (1479)
2023 (1816)
2022 (4259)
2021 (3990)
2020 (3343)
2019 (2094)
2018 (1536)
2017 (2037)
2016 (1948)
2015 (2705)
2014 (1890)
2013 (1350)
2012 (1307)
2011 (1270)
2010 (1166)
Location
Africa (31)
Alabama (3)
Arizona (1)
Arkansas (1)
Asia (1173)
Australia (182)
California (104)
Canada (26)
China (3)
Colorado (2)
Connecticut (8)
Delaware (4)
Europe (19823)
Florida (26)
Georgia (3)
Illinois (11)
India (3)
Indiana (5)
Iowa (1)
Japan (5)
Kansas (1)
Maryland (44)
Massachusetts (151)
Michigan (1)
Minnesota (4)
Missouri (1)
Nebraska (1)
New Jersey (37)
New York (32)
North Carolina (50)
Northern California (48)
Ohio (9)
Oregon (2)
Pennsylvania (57)
Puerto Rico (1)
Rhode Island (4)
South America (46)
Southern California (44)
Texas (7)
Utah (10)
Virginia (13)
Washington State (17)
Wisconsin (1)
38,155 Results for "oxford biomedica plc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Oxford Biomedica Business Update
Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led cell and gene therapy CDMO, today announces a business update for the year ending 31 December 2023.
December 7, 2023
·
6 min read
Deals
Oxford Biomedica completes acquisition of ABL Europe
Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led cell and gene therapy CDMO, today announces that, following the announcements on 20 September and 4 December 2023, it has today completed the acquisition of ABL Europe SAS (“ABL Europe”) from Institut Mérieux SA (“Institut Mérieux”).
January 29, 2024
·
4 min read
Business
Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023
Oxford Biomedica plc announces interim results for the six months ended 30 June 2023.
September 20, 2023
·
97 min read
Antibody-drug conjugate (ADC)
Roche Ups ADC Bet With $1B in Biobucks for Oxford BioTherapeutics
Roche’s up to $1 billion investment will provide access to Oxford BioTherapeutics’ antibody-drug conjugate platform for undisclosed cancer targets.
March 19, 2025
·
1 min read
·
Tristan Manalac
Press Releases
Oxford Biomedica announces CFO transition
July 17, 2024
·
3 min read
Press Releases
Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today
September 3, 2024
·
2 min read
Deals
Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position as a global pure-play CDMO
Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led cell and gene therapy CDMO, today announces that it has entered into a sale and purchase agreement (the “Agreement”) with TSGH SAS, a subsidiary of Institut Mérieux SA (“Institut Mérieux”), for the acquisition of ABL Europe SAS (“ABL Europe”) (the “Transaction”).
December 4, 2023
·
6 min read
Press Releases
Oxford Biomedica to host a free webinar showcasing its AAV expertise
August 27, 2024
·
2 min read
Business
Kyverna Therapeutics and Oxford Biomedica Sign License and Supply Agreement for LentiVector® Platform
Kyverna Therapeutics today announced a non-exclusive, multi-year license and supply agreement with Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”), a quality and innovation-led viral vector Contract and Development Manufacturing Organization (CDMO), enabling the use of LentiVector® with any Kyverna product.
September 20, 2023
·
4 min read
Press Releases
Oxford Biomedica – Half Year Trading Update and Notice of Interim Results
August 9, 2024
·
5 min read
1 of 3,816
Next